Meeting
2022 ASCO Annual Meeting
Prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma (mUC) treated with durvalumab (D) with or without tremelimumab (T) in the DANUBE study.
Authors
Carlos Stecca
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada
Carlos Stecca , Osama Abdeljalil Sr., Cindy Lu , Han Zhang , Erik T. Goluboff , Srikala S. Sridhar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Urothelial Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02516241
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4564)
DOI
10.1200/JCO.2022.40.16_suppl.4564
Abstract #
4564
Poster Bd #
55
Abstract Disclosures
Similar Posters
First Author: Matt D. Galsky
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Impact of PD-L1 expression on survival in patients with unresectable/recurrent gastric cancer receiving first-line chemotherapy without immune checkpoint inhibitors.
First Author: Hidekazu Hirano
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Benefit of immune checkpoint inhibitors (ICI) for patients with advanced esophageal squamous cell carcinoma and low PD-L1 expression: A systematic review and meta-analysis.
First Author: Mario Machado Lopes
Poster
2023 ASCO Annual Meeting
The metabolic activity assessed by 18F-FDG PET and its correlation with tumor immune status and prognosis in advanced biliary tract cancer patients treated with 1L GemCis plus durvalumab +/-tremelimumab.
First Author: Jeesun Yoon